Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.
Actively Recruiting
Researchers are studying the effects of IMVT-1402 in adults with mild to severe generalized myasthenia gravis, a condition affecting muscle strength. This Phase 3 trial aims to evaluate the efficacy, safety, and tolerability of IMVT-1402 as a treatment option compared to a placebo. The study is randomized and triple-blinded to ensure reliable results. Participants will receive one of two doses of IMVT-1402 or a placebo, all administered by subcutaneous injection once weekly. The treatment periods include an initial 12-week phase, followed by extended dosing periods of 14 weeks and 52 weeks for some groups. The study is designed to assess responses across these timeframes. During the trial, participants will be monitored through various assessments including the MG activities of daily living MG-ADL score and the Quantitative Myasthenia Gravis QMG score. The main outcome focuses on changes in MG-ADL from baseline to week 12. Safety and tolerability will also be tracked throughout the treatment and follow-up periods. The overall participation may last up to several months depending on the treatment group.